chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Blisters/ scabs are now healed where they wouldn't before.; Chills; fever range 101; Lethargy; Rash; aches; This spontaneous case was reported by a consumer and describes the occurrence of BLISTER, CHILLS, PYREXIA, LETHARGY, and RASH in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012120A and 031L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Bladder cancer.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 2 dosage form. On an unknown date, the patient experienced BLISTER, CHILLS, PYREXIA, LETHARGY, RASH, and PAIN IN EXTREMITY. The patient was treated with TYLENOL for Adverse event, at an unspecified dose and frequency. At the time of the report, BLISTER, CHILLS, PYREXIA, LETHARGY, RASH, and PAIN IN EXTREMITY outcome was unknown. Not Provided.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Most recent FOLLOW-UP information incorporated above On 13-May-2021.
Exposed to varicella 2 weeks ago, began rash 2 days ago has 15-20 papular lesion on trunk and neck. Taking Benedryl for itching.
Information was received from a lawyer regarding a case in litigation involving a male patient, age and medical history not provided. On or about 29-JAN-2014 the patient was inoculated with ZOSTAVAX vaccine for routine adult health maintenance and the prevention of shingles at a pharmacy. The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster. On or about 08-SEP-2016 the patient was treated by a physician for a blistering vesicular outbreak, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of ZOSTAVAX or despite receiving ZOSTAVAX for prevention of shingles, the patient suffered painful injuries and damages and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, pain, suffering and other damages. Additional information has been requested.
Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use; No adverse event; Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use), PRODUCT STORAGE ERROR (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use) and NO ADVERSE EVENT (No adverse event) in a 90-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 23-Nov-2022, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 23-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use) and PRODUCT STORAGE ERROR (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use) and PRODUCT STORAGE ERROR (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use).    No concomitant drug information was provided.  The BUD of the vaccine was provided was 17-Nov-2022.  No treatment medication information was provided.    This case was linked to US-MODERNATX, INC.-MOD-2023-704416 (Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-Jan-2023: Live Significant follow-up received included patient information updated, vaccinations details updated On 24-Jan-2023: Live follow-up received included no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704416:Master case
10/21/14 @0930 - Assessed L arm parent concern for swelling. L arm swollen, not red. Told to give Tylenol/Motrin for discomfort and warm pack as tol. 10/22/14- Morning Clinic visit. Nurse was contacted of NP diagnosis of cellulitis/ as reaction to vaccine.
Lot FK9894 was administered after the "beyond use" date of 7/3/2022.  Vaccine was picked up from the Health Department on 4/25/2022 and was to be used by 7/3/2022.  Vaccine was administered on 7/14/2022.  Awaiting feedback from Pfizer regarding vaccine viability.
This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced adverse reactions. The action taken with Covid-19 vaccine ad26.cov2.s was not applicable. The outcome of adverse reactions was not reported. This report was non-serious.
Nosebleed in right nostril. I VERY rarely get a nosebleed. From what I could feel, my nose was not sore, dry, or cracked to have made me bleed. The nosebleed occurred randomly and lasted approximately 10 minutes.
I had a rash all over my chest and arms where the vaccine was given. Flaky ears flaky eyes - prescribed steroids and creams for the rash. Ongoing pain and irritation and spreading through extremities.
Fever 100.4; Stiff Neck; Chills;body aches;Diarrhea; Joint Pain; Pain in Arm; Swelling;Redness;1/3 upper arm.
DOCTOR ORDERED DTAP/IPV VACCINE ON A 4-YEAR-OLD PATIENT. MEDICAL ASSITANT GAVE A PENTACEL INSTEAD OF A QUADRACEL. PARENT WAS CALLED AND MADE AWARE OF THE VACCINES GIVEN TO THE CHILD.
fever; This spontaneous case was reported by a physician and describes the occurrence of PYREXIA (fever) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever). At the time of the report, PYREXIA (fever) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.
ipol excursion was for 3 hours to a maximum temperature of 12.6°C with no reported adverse event; received IPOL from a vial that was exposed to a temperature excursion when punctured with no reported adverse event; Initial information received on 03-Aug-2023 regarding an unsolicited valid non-serious case received from other health professional.  This case involves a 14 years old male patient who received IPV (vero) [IPOL] from a vial that was exposed to a temperature excursion when punctured, excursion was for 3 hours to a maximum temperature of 12.6°c with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 29-Jun-2023, the patient received 0.5 mL dose of suspect IPV (vero), suspension for injection (batch number: W1A101M; expiry date: 10-Feb-2025) via unknown route in unknown administration site for Immunization from a vial that was exposed to a temperature excursion when punctured, excursion was for 3 hours to a maximum temperature of 12.6°c with no reported adverse event (product storage error) (poor quality product administered) (same day latency).  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event ipol excursion was for 3 hours to a maximum temperature of 12.6°c with no reported adverse event and was Unknown for the event received ipol from a vial that was exposed to a temperature excursion when punctured with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments:  US-SA-2023SA239251:01716102
Shingles; late 2nd dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of shingles in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 07-JUN-2022, the patient received the 1st dose of Shingrix. On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles (Verbatim: Shingles) and incomplete course of vaccination (Verbatim: late 2nd dose). The outcome of the shingles was not reported and the outcome of the incomplete course of vaccination was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.     It was unknown if the company considered the shingles to be related to Shingrix.   Additional Information: GSK Receipt Date: 30-JUN-2023 The reporter was a medical assistant. The reporter stated that the patient had a history of shingles; it was unknown if the episode of shingles occurred before or after the 1st dose of Shingrix. The reporter reported that the patient received the 1st dose of Shingrix and was late for the 2nd dose. The healthcare professional consented to follow-up via email. Till the time of reporting, the patient did not receive the 2nd dose of Shingrix, which led to incomplete course of vaccination.
This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination. No Medical History information was reported. On 30-Mar-2021 at 10:47 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 30-Mar-2021, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. Age of patient was reported as 67.68 for dose administered on 30-MAR-2021. No concomitant medications were reported. Batch number 019B21A underwent temperature excursion on 30-Mar-2021 with temperature 33 degrees Fahrenheit from 12:00 PM to 01:00 PM. This vial was moved to fridge on 23-Mar-2021 and beyond use date for the vial was reported as 22-Apr-2021. Product moved to clinic on 30-Mar-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisherbrand traceable temperature monitor at every hour. No treatment medications were reported.
I have been diagnosed with SIRVA in my right shoulder from an improperly administered flu vaccine.   I received my flu vaccine on 09/30/2020 at 4PM. I bled a lot when it was administered and the doctor commented ?Oh, do you normally bleed this much when you get vaccines?? I don?t. I later noted that the location of my shot was very high up on my arm, which I later learned is cause of my injury. Within a couple hours after the shot, my shoulder was very sore. By 9pm, the pain was so severe that I could not use my arm at all. The pain was excruciating for the next few days and then eventually peaked. I have had ongoing varying degrees of pain ever since.   I have pain in my right shoulder and right bicep area. The pain is dull when not using my arm, and sharp when I perform certain movements like trying to reach up high, rotating my arm outward and bringing it across my chest. Sleeping is extremely difficult, and I wake up from pain with even a slight movement. I cannot sleep on the affected side at all.  I started physical therapy on October 27, 2020. After four PT sessions, I had not seen any improvement. I decided to discontinue PT because I decided to seek alternative treatment with Dr., plus I did not feel comfortable being in an enclosed space with multiple people given the high numbers of Covid.  I received a steroid injection into my shoulder on December 16, 2020, which did not do anything to alleviate my pain.  On February 5, 2021 I underwent a new procedure with Dr. He used a Tenex device to ?clean out? the affected areas. I?m still waiting to see how/if my injury heals.  I continue to have constant pain to this day.
Slight Fever, body aches, sore throat, headache, nausea, diarrhea.  Took Motrin and rested.
11-10-06 Left arm sore weak heavy; 11-11-06 no ss; 11-12-06 no ss; 11-13-06 no ss; 11-14-06 numbness to anterior left side, left eye twitch, speech slurred, left side of face edema; 11-15-06 ss worse.  11/20/06 Received medical records which reveal patient seen in ER with numbness of left face, left eye weakness, left facial swelling, left facial droop.  Left eye was tearing more & was drooling from left side of mouth.  Treated w/steroids & antiviral.  D/C to home from ER to f/u with PCP. Final DX: Bells Palsy./ss
pt devel pruritic, erythematous macular rash over trunk & neck 5-10 mins following vax; lungs clear;
pt recvd 1 dose of Engerix-B & exp paresthesia; onset 1 wk to 10 days; sx persist; h/a onset immed duration 3 days; pain in back & shoulders-onset 2-3 days; duration 3 days; pain in neck-onset 1 wk; confusion duration 2 days;
Fatigue; A bad headache; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Fatigue) and HEADACHE (A bad headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FATIGUE (Fatigue) and HEADACHE (A bad headache). At the time of the report, FATIGUE (Fatigue) and HEADACHE (A bad headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       This case was linked to MOD-2021-026536 (Patient Link).
faintness several minutes p/vax p/child witnessed sibling syncopal attach child felt dizzy, mild diaphoretic, sl pale w/o loss of consciousness;child placed supine for a while & recovered;
Pt recv vax on 12/23/98; on 12/24/98 pt exp welts rash on face, scalp, neck to shoulder blades, itching &burning; tx=Benadryl
PATIENT RECIEVED COVID PFIZER BIVALENT VACCINE ASSUMING IT WAS GOING TO BE IS INITAL DOSE SERIOUS DUE TO THE FACT THAT THIS PRIOR COVID SERIOUS (SPUTNIK V) ARE NOT RECOGNIZED BY THE US.
big mass; extreme itching; extreme burning; Rash, has appearance of chickenpox/rash begins on left side of patient's neck and extends down their left shoulder and onto left, upper chest; Blistering in the form of one /blistery rash on chest; This non-serious case was reported by a consumer via call center representative and described the occurrence of rash in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included PNEUMOCOCCAL VACCINE (PNEUMONIA VACCINE) for prophylaxis.   On 14-MAR-2023, the patient received the 1st dose of Shingrix (left arm) and PNEUMONIA VACCINE. On 15-MAR-2023, 1 days after receiving Shingrix, the patient experienced rash (Verbatim: Rash, has appearance of chickenpox/rash begins on left side of patient's neck and extends down their left shoulder and onto left, upper chest) and blistery rash (Verbatim: Blistering in the form of one /blistery rash on chest). On an unknown date, the patient experienced mass (Verbatim: big mass), pruritus (Verbatim: extreme itching) and burning sensation (Verbatim: extreme burning). The outcome of the rash, blistery rash, mass, pruritus and burning sensation were not recovered/not resolved.   It was unknown if the reporter considered the rash, blistery rash, mass, pruritus and burning sensation to be related to Shingrix.     It was unknown if the company considered the rash, blistery rash, mass, pruritus and burning sensation to be related to Shingrix.   Additional Information: GSK Receipt Date: 16-MAR-2023, 17-MAR-2023 and 28-MAR-2023 The reporter was husband of patient.  The patient received a pneumonia vaccine at the same time she received the first Shingrix vaccine in the left arm.. The patient woke the next morning to a blistery rash at over her chest and was in the form of one, big mass. The rash began on left side of patient's neck and extends down their left shoulder and onto left, upper chest.  The rash had appearance of chickenpox, except it was in a mass instead of spread out.  The rash had not resolved and she reported using HC 2.5% Cream to help with the extreme itching and burning. The reporter reported that her physician was out of the country and did not want to see another physician. The reporter reported wanting to let patient call in to report details of adverse event, all details provided by reporter was reported.  The reporter declined to report patient's demographics. 1 days after receiving PNEUMONIA VACCINE, the patient experienced rash, blistery rash. On an unknown date after receiving PNEUMONIA VACCINE, the patient experienced mass, pruritus and burning sensation. It was unknown if the reporter considered the rash, blistery rash, mass, pruritus and burning sensation to be related to PNEUMONIA VACCINE.  The reporter did not consent to follow-up. As per latest follow up, the event onset date was captured conservatively.
his low-level chronic tinnitus and hearing loss became extreme and had stayed that way ever since, 30 days ago, with no relief; his low-level chronic tinnitus and hearing loss became extreme and had stayed that way ever since, 30 days ago, with no relief; his low-level chronic tinnitus and hearing loss became extreme and had stayed that way ever since, 30 days ago, with no relief; This is a spontaneous report from a contactable consumer (patient). A male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via unspecified route of administration in left arm on 30Mar2021 at 11:45 at single dose for COVID-19 immunization. The relevant medical history included low-level chronic tinnitus and idiopathic hearing loss from unspecified date. Concomitant medications were reported as none. On 01Apr2021 at 03:00 AM, one day after the first (AND ONLY) Pfizer injection, his low-level chronic tinnitus and hearing loss became extreme and had stayed that way ever since, 30 days ago, with no relief. Out of fear of making the tinnitus even worse, he had decided not to get the second Pfizer shot. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The outcome of the events was not recovered.  Information about Batch/lot number has been requested.
My son received the second dose of Pfizer vaccine on 26NOV2021, and had no adverse reaction other than fatigue. On 06JAN2022 6 weeks following vaccination, he began to experience petechiae on both legs and feet, progressing in severity. On 09JAN2022 I took him to Urgent Care to be seen regarding the rapidly spreading petechiae and purpura now all over his legs and feet including the soles of the feet. Following bloodwork and COVID and FLU tests (both negative) he was seen the following day 10JAN2022 by his pediatrician who diagnosed Henoch-Schonlein Purpura.  He has had no illness that we know of that could have triggered the HSP, which is typically seen following viral illness but could come from any number of triggers. I share the information on VAERS not because I think the vaccine caused this condition but because I want to contribute information in case there is an increase of HSP cases surrounding vaccination and/or covid exposure. Thank you for your work to monitor vaccine safety and effectiveness!
On 05/01/2000, the patient developed "bumps described as a few papular lesions on trunk, some with hard centers, one with an open lesion." The patient was seen by a physician. Additional information has been requested.